A coronavirus vaccine candidate from pharmaceutical company Pfizer has shown potential in healthy volunteers. Stocks jumped on the announcement Wednesday.

The experimental vaccine developed by Pfizer and the biotech firm BioNTech produced promising results in early-stage human trials, in which 45 volunteers were given doses of the vaccine. Each participant received 10, 30, or 100 microgram doses of the vaccine or a placebo.